[Retracted] miR‑222 regulates sorafenib resistance and enhance tumorigenicity in hepatocellular carcinoma
Affiliations: Department of Hepatopancreatobiliary Surgery, The First Hospital, Jilin University, Changchun, Jilin Province, P.R. China
- Published online on: November 1, 2021 https://doi.org/10.3892/ijo.2021.5280
- Article Number: 100
Copyright : © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].
This article is mentioned in:
Int J Oncol 45: [Related article:] 1537-1546, 2014; DOI: 10.3892/ijo.2014.2577
Following the publication of this paper, it was drawn to the Editors' attention by a concerned reader that the flow cytometric data in Fig. 3A and western blotting data featured in Figs. 3C and 7 were strikingly similar to data appearing in different form in other articles that shared some of the same authors. Owing to the fact that the contentious data in the above article were already under consideration for publication, or had already been published, elsewhere prior to its submission to International Journal of Oncology, the Editor has decided that this paper should be retracted from the Journal. After having been in contact with the authors, they agreed with the decision to retract the paper. The Editor apologizes to the readership for any inconvenience caused.